Skin Cancer Diagnostics Market is expected to reach US$ 5,480.45 Million by 2028

PRESS RELEASE BY The Insight Partners 28 Feb 2022

Share this press on

Non-melanoma Segment by Type to Hold Largest Share of Skin Cancer Diagnostics Market During 2021–2028


According to our new research study on "Skin Cancer Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, and Screening Type," the skin cancer diagnostics market size is expected to reach US$ 5,480.45 million by 2028 from US$ 3,364.46 million in 2021; it is estimated to grow at a CAGR of 7.2% from 2021 to 2028. The report highlights trends prevailing in the skin cancer diagnostics market and factors governing its growth. The increasing incidence of skin cancer and launch of new product are driving the growth of the market. However, barriers to early skin cancer diagnostics in low and middle-income countries hinders the skin cancer diagnostics market growth.


Based on type, the skin cancer diagnostics market is segmented into melanoma and non-melanoma. The non-melanoma segment held the largest share of the skin cancer diagnostics market in 2021 and is expected to register the highest CAGR during the forecast period. Non-melanoma skin cancers are more frequent than melanoma skin cancer. Non-melanoma comprises of Merkel cell carcinoma, basal cell carcinomas and squamous cell carcinomas. These are completely curable through surgery and are rarely lethal, however, surgical treatment is painful and disfiguring. It is said that the incidences of non-melanoma skin cancers are difficult to determine due to inefficient reliable registration. Although countries such as the US, Canada, and Australia have conducted specific studies that indicates that the prevalence of non-melanoma cancers has increased significantly between 1960s–1980s.    

Skin Cancer Diagnostics Market

Skin Cancer Diagnostics Market

Skin Cancer Diagnostics Market Size & Growth | Forecast 2028

Download Free Sample

Global Skin Cancer Diagnostics Market Size, Share, and COVID-19 Impact Analysis - by Type (Melanoma and Non-Melanoma), Screening Type (Blood Tests, Dermatoscopy, Imaging Tests, Lymph Node Biopsy, and Skin Biopsy), and Regional Forecast (2021–2028)


The major causes non-melanoma skin cancers are exposure to higher ultraviolet radiation levels. Thus, the incidences are expected to be higher in the countries lies in decreasing latitude that have higher levels of ultraviolet radiations. According to the Skin Cancer Foundation, it is stated that over 5, 400 people globally die of non-melanoma skin cancer every month. Also, the incidences of Merkel cell carcinoma have increased by 95% between 2000–2013, however, this type is rare and aggressive form of skin cancer. Likewise, region like Europe is at higher risk of people suffering from NMSC, as in the region alone ~15 million outdoor workers are exposed to sun during their working hours without knowing the risks.

Various countries across the world are raising awareness with respect to non-melanoma skin cancer. For instance, in June 2019, The European Cancer Patient Coalition (ECPC) and the European Academy of Dermatology and Venereology (EADV) has launched the Global Non-Melanoma Skin Cancer (NMSC) Awareness Day to raise awareness of NMSC. Such initiatives are expected to enhance the awareness and lead to increasing demand for diagnosis. Thus, owing to the growing awareness, the skin cancer diagnostics market is expected to grow in the coming years.  


Impact of COVID-19 Pandemic in North American Region

The outbreak COVID-19 has been extraordinary and has resulted in dramatic reductions in non-urgent medical services. During the year 2020 to mid-2021, countries in the region have imposed lockdowns which have delayed the hospital visits. Thus, it is estimated that delays may have shown critical health impact on several health conditions, including delayed diagnosis for melanoma and other skin cancers. Hospitals has experienced drastic reduction in the skin biopsies. For instance, according to a research article published in March 2021, universal healthcare claims in Ontario showed drastic drop in total skin biopsies. There was 15% drop in biopsies from the expected rate. There were huge backlogs in skin biopsies during the lockdown. Similarly, the US faced delayed in obtaining diagnosis for skin cancer which further delayed treatment and its management. The delayed has also increased the number of death due to skin cancer. In 2020, melanoma comprised of nearly 5.6% of all cancer cases in the US and caused maximum deaths due to skin cancer. Consequently, the lockdown has shown a significant reduction in skin cancer surgery that has manifested as increased morbidity, mortality, and decreased long-term survival., The outbreak of COVID-19 had a profound impact on the routine management of skin cancer services. Thus, the pandemic has negatively impacted the market for skin cancer diagnosis. However, the reopening of all medical services is expected to increase the demand for skin cancer diagnosis further leading to vital skin cancer diagnostics market growth.


SkylineDx BV; AMLo Biosciences Limited; NeraCare GmbH; DermLite LLC; bioMerieux SA; Veriskin Inc.; Castle Biosciences, Inc.; DermTech Inc.; HOFFMANN-LA ROCHE LTD., and Michelson Diagnostics Ltd are among the leading companies operating in the skin cancer diagnostics market.


The report segments the global skin cancer diagnostics market as follows:


The skin cancer diagnostics market is segmented on the basis of type, and screening type. Based on type, the market is segmented into melanoma and non-melanoma. By screening type, the skin cancer diagnostics market is segmented into skin biopsy, dermatoscopy, lymph node biopsy, imaging tests, and blood tests.

Contact Us
Phone: +1-646-491-9876
Email Id:

Download Free PDF Brochure